They found both previously known and novel mutations significantly linked to EGFR activation ... linked to cancer progression and drug resistance across various cell types. The researchers used ...

Because patients with wild-type EGFR tumors fared poorly with upfront TKIs, EGFR mutation testing is necessary both to identify patients who are candidates for more tolerable first-line TKI ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

They found both previously known and novel mutations significantly linked to EGFR activation and drug response, demonstrating the method's precision and revealing new pathways affecting tumor ...

Dizal announces positive pooled data of sunvozertinib in EGFR TKI-resistant NSCLC: Shanghai, China Friday, December 13, 2024, 18:00 Hrs [IST] Dizal, a biopharmaceutical company co ...

Comprehensive biomarker testing can identify EGFR or other mutations in your lung cancer. Learn the benefits of testing and how it can help shape treatment.

Greater ORR of 55.6% was seen in patients with EGFR sensitizing and T790M double mutations (78% had received third-generation EGFR-TKI treatment in prior lines of therapy). Sunvozertinib was ...

Study demonstrates how metabolic imaging differentiates high and low oxidative phosphorylation (OXPHOS) subtypes of ...

In a recent study Dr. Charles Swanton led a study published in Nature (2019) that explored the link between air pollution and ...

The FDA has granted Breakthrough Therapy designation to sacituzumab tirumotecan for patients with advanced or metastatic ...

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer ... the U.S. could have an actionable mutation also called a biomarker such as EGFR,” says Dr. Hossein Borghaei ...